Cargando…

Comparative effect of metformin versus sulfonylureas with dementia and Parkinson’s disease risk in US patients over 50 with type 2 diabetes mellitus

INTRODUCTION: Type 2 diabetes is a risk factor for dementia and Parkinson’s disease (PD). Drug treatments for diabetes, such as metformin, could be used as novel treatments for these neurological conditions. Using electronic health records from the USA (OPTUM EHR) we aimed to assess the association...

Descripción completa

Detalles Bibliográficos
Autores principales:	Newby, Danielle, Linden, Andrew Brent, Fernandes, Marco, Molero, Yasmina, Winchester, Laura, Sproviero, William, Ghose, Upamanyu, Li, Qingqin S, Launer, Lenore J, van Duijn, Cornelia M, Nevado-Holgado, Alejo J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Epidemiology/Health services research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9478804/ https://www.ncbi.nlm.nih.gov/pubmed/36109050 http://dx.doi.org/10.1136/bmjdrc-2022-003036

Ejemplares similares

The relationship between isolated hypertension with brain volumes in UK Biobank
por: Newby, Danielle, et al.
Publicado: (2022)

Associations Between Brain Volumes and Cognitive Tests with Hypertensive Burden in UK Biobank
por: Newby, Danielle, et al.
Publicado: (2021)

Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
por: Mamtani, Ronac, et al.
Publicado: (2014)

Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas
por: Chu, Patricia Y., et al.
Publicado: (2020)

Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas
por: Dawed, Adem Y., et al.
Publicado: (2021)

Association of metformin, sulfonylurea and insulin use with brain structure and function and risk of dementia and Alzheimer’s disease: Pooled analysis from 5 cohorts
por: Weinstein, Galit, et al.
Publicado: (2019)

Red blood cell indices and anaemia as causative factors for cognitive function deficits and for Alzheimer’s disease
por: Winchester, Laura M., et al.
Publicado: (2018)

Adipose Tissue, Muscle, and Function: Potential Mediators of Associations Between Body Weight and Mortality in Older Adults With Type 2 Diabetes
por: Murphy, Rachel A., et al.
Publicado: (2014)

Mental disorders and intimate partner violence perpetrated by men towards women: A Swedish population-based longitudinal study
por: Yu, Rongqin, et al.
Publicado: (2019)

Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

Association of vitamin B(12) deficiency in people with type 2 diabetes on metformin and without metformin: a multicenter study, Karachi, Pakistan
por: Miyan, Zahid, et al.
Publicado: (2020)

Validation of UK Biobank data for mental health outcomes: A pilot study using secondary care electronic health records
por: Li, Zhenpeng, et al.
Publicado: (2022)

Metformin and breast and gynecological cancer risk among women with diabetes
por: Soffer, Diana, et al.
Publicado: (2015)

Metformin Use in Prediabetes Among U.S. Adults, 2005–2012
por: Tseng, Eva, et al.
Publicado: (2017)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
por: Muthukrishnan, J., et al.
Publicado: (2012)

Health Beliefs Associated With Metformin Use Among Insured Adults With Prediabetes
por: McEwen, Laura N., et al.
Publicado: (2022)

Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study
por: Donnelly, Louise A., et al.
Publicado: (2020)

Potential Impact of Prescribing Metformin According to eGFR Rather Than Serum Creatinine
por: Tuot, Delphine S., et al.
Publicado: (2015)

Association between metformin and neurodegenerative diseases of observational studies: systematic review and meta-analysis
por: Ping, Fan, et al.
Publicado: (2020)

Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGES-Reykjavik Study
por: Olafsdottir, Elin, et al.
Publicado: (2011)

Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis
por: Abolhassani, Nazanin, et al.
Publicado: (2023)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma
por: Toomey, Paul, et al.
Publicado: (2017)

Efficacy of metformin versus sulfonylurea derivative in HNF4A-MODY
por: Oosterom, Nicole, et al.
Publicado: (2022)

Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study
por: Au Yeung, Shiu Lun, et al.
Publicado: (2019)

Use of metformin following a population-level intervention to encourage people with pre-diabetes to enroll in the National Diabetes Prevention Program
por: Hurst, Thomas E, et al.
Publicado: (2021)

Determining the Molecular Pathways Underlying the Protective Effect of Non-Steroidal Anti-Inflammatory Drugs for Alzheimer's Disease: A Bioinformatics Approach
por: Nevado-Holgado, Alejo J, et al.
Publicado: (2016)

Cumulative Kidney Complication Risk by 50 Years of Type 1 Diabetes: The Effects of Sex, Age, and Calendar Year at Onset
por: Costacou, Tina, et al.
Publicado: (2018)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
por: Komajda, Michel, et al.
Publicado: (2008)

Dementia risk in the general population: large-scale external validation of prediction models in the AGES-Reykjavik study
por: Vonk, Jet M. J., et al.
Publicado: (2021)

Lifestyle and Metformin Interventions Have a Durable Effect to Lower CRP and tPA Levels in the Diabetes Prevention Program Except in Those Who Develop Diabetes
por: Goldberg, Ronald B., et al.
Publicado: (2014)

Sulfonylureas (not metformin) improve survival of patients with diabetes and resectable pancreatic adenocarcinoma: erratum
Publicado: (2017)

The Effectiveness and Safety of Metformin Compared to Sulfonylureas in Diabetic Nephropathy: A Systematic Review
por: Boddepalli, Chinmayi Sree, et al.
Publicado: (2022)

Glucagon-like peptide 1 agonists for treatment of patients with type 2 diabetes who fail metformin monotherapy: systematic review and meta-analysis of economic evaluation studies
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2020)

Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK
por: Gonzalez Perez, Antonio, et al.
Publicado: (2023)

Sociodemographic and behavioral characteristics associated with self-reported diagnosed diabetes mellitus in adults aged 50+ years in Ghana and South Africa: results from the WHO-SAGE wave 1
por: Tarekegne, Fitsum Eyayu, et al.
Publicado: (2018)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
por: Kwon, Christina S., et al.
Publicado: (2018)

Improvements in Glycemic Control in Type 2 Diabetes Patients Switched From Sulfonylurea Coadministered With Metformin to Glyburide-Metformin Tablets
por: Duckworth, Wiliam
Publicado: (2003)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
por: George, Joe
Publicado: (2015)

Comparative Safety of Sulfonylurea and Metformin Monotherapy on the Risk of Heart Failure: A Cohort Study
por: Roumie, Christianne L., et al.
Publicado: (2017)

Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
por: Baker, Matthew C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_fg8rm32mqoivlm8l93dl1m2uqb